Despite the recent failure of TH-302 to show significant clinical benefits in Phase III clinical trials of sarcoma and pancreatic cancer, future clinical trials combining hypoxic tumor cell targeted agents with anti-angiogenic agents, such as TH-302 in combination with sunitinib or other VEGF inhibitors, may be efficacious to combat cancer and improve patient survival. Here, VEGFA is linked to pancreatic neoplasm.